ASSET PURCHASE AGREEMENT BY AND AMONG JANSSEN BIOTECH, INC. AND ORBIT BIOMEDICAL LIMITED dated as of March 29, 2018Asset Purchase Agreement • January 11th, 2021 • Gyroscope Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • New York
Contract Type FiledJanuary 11th, 2021 Company Industry JurisdictionThis Asset Purchase Agreement (this “Agreement”), dated as of March 29, 2018, is entered into by and between Janssen Biotech, Inc., a Pennsylvania corporation (“Seller”), Orbit Biomedical Limited, a limited company organized under the Laws of England and Wales (“Buyer”). Seller and Buyer are sometimes individually referred to herein as a “Party” and are sometimes collectively referred to herein as the “Parties.”
ContractExclusive Patent and Non-Exclusive Know-How Licence Agreement • January 11th, 2021 • Gyroscope Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • England
Contract Type FiledJanuary 11th, 2021 Company Industry JurisdictionCertain confidential information contained in this document, marked by [**], has been omitted because the information (i) is not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.
ContractExclusive Patent Licence Agreement • January 11th, 2021 • Gyroscope Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • England
Contract Type FiledJanuary 11th, 2021 Company Industry JurisdictionCertain confidential information contained in this document, marked by [**], has been omitted because the information (i) is not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.
ContractLicense Agreement • January 11th, 2021 • Gyroscope Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • England
Contract Type FiledJanuary 11th, 2021 Company Industry JurisdictionCertain confidential information contained in this document, marked by [**], has been omitted because the information (i) is not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.